Olabe Julie, Garrouste Cyril, Pereira Bruno, Colosio Charlotte, Thierry Antoine, Rerolle Jean-Philippe, Bertrand Dominique, Jaureguy Maïté, Goblin Léonard, Buchler Mathias, Le Meur Yannick, Chatelet Valerie, Augusto Jean-François, Tauveron Igor, Batisse-Lignier Marie, Heng Anne Elizabeth
Diabetology and Metabolic Diseases Department, University Hospital, Clermont-Ferrand, France.
Nephrology, Dialysis and Transplantation Department, University Hospital, Clermont-Ferrand, France.
Clin Transplant. 2025 Mar;39(3):e70116. doi: 10.1111/ctr.70116.
Post-transplant diabetes mellitus (PTDM) is a common, dynamic complication after kidney transplantation (KT) that may resolve over time. To better understand and prevent PTDM, we analyzed its prevalence, evolution, and influencing factors.
Data from the French national ASTRE database at different post-transplantation periods (P) were analyzed. PTDM was defined by fasting blood glucose (FBG) ≥1.26 g/L, HbA1c ≥ 6.5%, or the use of hypoglycemic medications in kidney transplant recipients without diabetes. Patient trajectories were identified using group-based trajectory models (GBTM), and associated factors were examined.
Among 2898 patients, PTDM prevalence was 27.3% at P1 (>M2, ≤M6), 21.3% at P2 (>M6, ≤M18), 19.8% at P3 (>M18, ≤M30), and 19.9% at P4 (>M30, ≤M42). Analysis of 1825 patients identified four trajectories: no PTDM (67%), late-onset PTDM (6%), remission after P1 (10%), and early, persistent PTDM (17%). Late-onset PTDM was linked to history of cardiovascular disease, higher BMI at transplantation, HCV positive status, and weight gain. Early, persistent PTDM was associated with older age, higher BMI, HVC positive status, history of cardiovascular disease, and tacrolimus use. PTDM remission was linked to lower BMI. Corticosteroids contributed to both late-onset and persistent PTDM, while switching between tacrolimus and cyclosporine did not significantly affect progression.
This study confirmed the high prevalence and dynamic nature of PTDM after transplantation, emphasizing the critical role of pretransplant cardiovascular disease, BMI, and early post-transplant weight gain in the onset or remission of PTDM.
移植后糖尿病(PTDM)是肾移植(KT)后常见的动态并发症,可能会随时间缓解。为了更好地理解和预防PTDM,我们分析了其患病率、演变情况及影响因素。
分析了法国国家ASTRE数据库中不同移植后时期(P)的数据。PTDM的定义为肾移植受者空腹血糖(FBG)≥1.26 g/L、糖化血红蛋白(HbA1c)≥6.5%,或在无糖尿病的肾移植受者中使用降糖药物。使用基于群体的轨迹模型(GBTM)确定患者轨迹,并检查相关因素。
在2898例患者中,P1期(>M2,≤M6)PTDM患病率为27.3%,P2期(>M6,≤M18)为21.3%,P3期(>M18,≤M30)为19.8%,P4期(>M30,≤M42)为19.9%。对1825例患者的分析确定了四种轨迹:无PTDM(67%)、迟发性PTDM(6%)、P1期后缓解(10%)和早期持续性PTDM(17%)。迟发性PTDM与心血管疾病史、移植时较高的体重指数(BMI)、丙型肝炎病毒(HCV)阳性状态和体重增加有关。早期持续性PTDM与年龄较大、BMI较高、HVC阳性状态、心血管疾病史和使用他克莫司有关。PTDM缓解与较低的BMI有关。皮质类固醇促成了迟发性和持续性PTDM,而他克莫司和环孢素之间的转换对病情进展没有显著影响。
本研究证实了移植后PTDM的高患病率和动态性质,强调了移植前心血管疾病、BMI以及移植后早期体重增加在PTDM发病或缓解中的关键作用。